Taiwan TCM Pavilion Captivates Global Audience at CPHI Frankfurt 2025

The Taiwan Traditional Chinese Medicine (TCM) Pavilion made a significant impact at CPHI Frankfurt 2025, which is taking place from October 28 to 30. The event attracted a diverse group of pharmaceutical professionals and distributors eager to explore partnerships in evidence-based herbal innovations and original equipment manufacturing (OEM) and original design manufacturing (ODM) collaborations.

Organized by the Department of Chinese Medicine and Pharmacy (DCMP) under Taiwan’s Ministry of Health and Welfare (MOHW), and executed by the Taiwan Institute of Economic Research (TIER), the Pavilion showcases Taiwan’s unique approach to traditional medicine. This approach effectively blends a rich clinical heritage with modern scientific validation and robust regulatory frameworks.

Highlighting Evidence-Based Innovations

On its opening day, the Pavilion was featured on the CPHI Newsbeat Stage, providing an opportunity to present its narrative to international industry press. During the session, TIER introduced how Taiwan’s TCM model is being redefined through scientific advancements. This was followed by a brief interview with Raman Sehgal, the host of the prominent life sciences podcast, “Molecule to Market.” The event saw attendance from approximately ten media outlets, amplifying the Pavilion’s reach.

A key discussion point was the herbal formula NRICM101, developed in response to the COVID-19 pandemic. Supported by multiple peer-reviewed studies, NRICM101 has demonstrated effectiveness in reducing severe outcomes associated with the virus. The Pavilion also showcased NRICM102, a formula designed to inhibit viral activity and reduce inflammation, with users showing a remarkable 74% lower mortality rate compared to those not using the formula.

Showcasing Taiwan’s TCM Industry

The Pavilion features five leading Taiwanese enterprises: Chuang Song Zong, Li Kang Biotech, Timing Pharmaceutical, Taiwan Three Mast, and Grape King Bio. These companies represent Taiwan’s dynamic TCM industry, emphasizing research excellence, innovative product development, and good manufacturing practice (GMP)-certified manufacturing tailored for global markets.

Dr. Yi-Chang Su, Director of the DCMP and NRICM, expressed confidence in the Pavilion’s potential to foster international partnerships. “Taiwan’s integration of TCM and modern science continues to earn global recognition,” he stated. “We look forward to building partnerships that bring trusted, evidence-based TCM to broader markets.”

Throughout the exhibition, delegates from the Pavilion are actively engaging with pharmaceutical companies, regulatory experts, and industry promotion organizations from Europe and the Americas. The aim is to explore potential collaborations that could advance global health through Taiwan’s evidence-based TCM model.

This strong international presence at CPHI Frankfurt 2025 underscores Taiwan’s commitment to integrating traditional medicine with contemporary scientific practices, positioning it as a leader in the global healthcare landscape.